Gail J. Roboz, MD, Weill Cornell Medical Center

Articles

CPX-351 in Newly Diagnosed Secondary AML

July 20th 2020

Differentiation Syndrome and IDH Inhibitors in AML

July 20th 2020

IDH Inhibitors and MDS

July 20th 2020

IDH1/2 Inhibitors for AML

July 20th 2020

IDH Mutations in AML

July 20th 2020

FLT3 Triplet Regimens for AML

July 20th 2020

Monitoring Response to Venetoclax Regimens in AML

July 20th 2020

Venetoclax in AML: Safety Profile

July 20th 2020

Optimal Use of Venetoclax in AML

July 20th 2020

VIALE Studies in AML

July 20th 2020

Utilization of Second-Generation FLT3 Inhibitors in AML

July 20th 2020

Second-Generation FLT3 Inhibitors in AML

July 20th 2020

FLT3-Mutated AML: Midostaurin and Chemotherapy

July 20th 2020

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

July 20th 2020

FLT3 Genetic Alterations in AML

July 20th 2020

Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

August 30th 2017

Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.

Dr. Gail Roboz on Molecular Mutations in MDS

May 2nd 2015

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).

Dr. Roboz on Improving the Standard Treatment of AML

November 30th 2012

Gail J. Roboz, MD, associate professor of medicine, director of the Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City, explains research into potential improvements to the standard treatment of AML.